The Neuropeptide Y Y1 Receptor: A Diagnostic Marker? Expression in MCF-7 Breast Cancer Cells Is Down-Regulated by Antiestrogens In Vitro and in Xenografts

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Memminger, Martin ^a   Keller, Max ^a   Lopuch, Miroslaw ^a   Pop, Nathalie ^a   Bernhardt, Günther ^a   von Angerer, Erwin ^a   Buschauer, Armin ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1 NAPHTHALENESULFONIC ACID [4 [(4 AMINO 2 QUINAZOLINYLAMINO)METHYL]CYCLOHEXYLMETHYL]AMIDE; AFIMOXIFENE; CALCIUM ION; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; FULVESTRANT; N [2 [1,2 DIHYDRO 3,5(4H) DIOXO 1,2 DIPHENYL 1,2,4 TRIAZOL 4 YL]ETHYL] N2 [[1 [2 [4 [5,11 DIHYDRO 6(6H) OXODIBENZ[B,E]AZEPIN 11 YL] 1 PIPERAZINYL] 2 OXOETHYL]CYCLOPENTYL]ACETYL]ARGININAMIDE; NALPHA (DIPHENYLACETYL) N (4 HYDROXYBENZYL) DEXTRO ARGININAMIDE; NEUROPEPTIDE Y1 RECEPTOR; TAMOXIFEN CITRATE; TUMOR MARKER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BINDING ASSAY; BREAST CANCER; CALCIUM CELL LEVEL; CANCER CELL CULTURE; CANCER GROWTH; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DISEASE MARKER; DOWN REGULATION; DRUG SENSITIVITY; DRUG STRUCTURE; DRUG TARGETING; FEMALE; GENE OVEREXPRESSION; IC 50; IN VITRO STUDY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; RADIOASSAY; TUMOR XENOGRAFT; UPREGULATION;

ANIMALS; ARGININE; BREAST NEOPLASMS; CALCIUM; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; ESTRADIOL; ESTROGEN RECEPTOR MODULATORS; FEMALE; HUMANS; MICE; MICE, NUDE; NEUROPEPTIDE Y; RECEPTORS, ESTROGEN; RECEPTORS, NEUROPEPTIDE Y; TAMOXIFEN;

MUS MUSCULUS;

EID: 84870908868     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0051032     Document Type: Article

References (50)

1. Pedrazzini T, Pralong F, Grouzmann E, (2003) Neuropeptide Y: the universal soldier. Cell Mol Life Sci 60: 350-377.
2. Michel MC, Beck-Sickinger A, Cox H, Doods HN, Herzog H, et al. (1998) XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors. Pharmacol Rev 50: 143-150.
3. Larhammar D, Blomqvist AG, Yee F, Jazin E, Yoo H, et al. (1992) Cloning and functional expression of a human neuropeptide Y/peptide YY receptor of the Y1 type. J Biol Chem 267: 10935-10938.
4. Motulsky HJ, Michel MC, (1988) Neuropeptide Y mobilizes Ca2+ and inhibits adenylate cyclase in human erythroleukemia cells. Am J Physiol 255: E880-885.
5. Aakerlund L, Gether U, Fuhlendorff J, Schwartz TW, Thastrup O, (1990) Y1 receptors for neuropeptide Y are coupled to mobilization of intracellular calcium and inhibition of adenylate cyclase. FEBS Lett 260: 73-78.
6. Reubi JC, (2003) Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 24: 389-427.
7. Reubi JC, Maecke HR, (2008) Peptide-based probes for cancer imaging. J Nucl Med 49: 1735-1738.
8. Körner M, Reubi JC, (2007) NPY receptors in human cancer: a review of current knowledge. Peptides 28: 419-425.
9. Zwanziger D, Khan IU, Neundorf I, Sieger S, Lehmann L, et al. (2008) Novel chemically modified analogues of neuropeptide Y for tumor targeting. Bioconjug Chem 19: 1430-1438.
10. Zwanziger D, Beck-Sickinger AG, (2008) Radiometal targeted tumor diagnosis and therapy with peptide hormones. Curr Pharm Des 14: 2385-2400.
11. Khan IU, Zwanziger D, Bohme I, Javed M, Naseer H, et al. (2010) Breast-cancer diagnosis by neuropeptide Y analogues: from synthesis to clinical application. Angew Chem Int Ed Engl 49: 1155-1158.
12. Gilaberte Y, Roca MJ, Garcia-Prats MD, Coscojuela C, Arbues MD, et al. (2012) Neuropeptide Y expression in cutaneous melanoma. J Am Acad Dermatol 66: e201-e208.
13. Lu C, Everhart L, Tilan J, Kuo L, Sun CCJ, et al. (2010) Neuropeptide Y and its Y2 receptor: potential targets in neuroblastoma therapy. Oncogene 29: 5630-5642.
14. Chatenet D, Cescato R, Waser B, Erchegyi J, Rivier JE, et al. (2011) Novel dimeric DOTA-coupled peptidic Y1-receptor antagonists for targeting of neuropeptide Y receptor-expressing cancers. EJNMMI Res 1: 21/01-11.
15. Reubi JC, Gugger M, Waser B, Schaer JC, (2001) Y(1)-mediated effect of neuropeptide Y in cancer: breast carcinomas as targets. Cancer Res 61: 4636-4641.
16. Kuang WW, Thompson DA, Hoch RV, Weigel RJ, (1998) Differential screening and suppression subtractive hybridization identified genes differentially expressed in an estrogen receptor-positive breast carcinoma cell line. Nucleic Acids Res 26: 1116-1123.
17. Amlal H, Faroqui S, Balasubramaniam A, Sheriff S, (2006) Estrogen up-regulates neuropeptide Y Y1 receptor expression in a human breast cancer cell line. Cancer Res 66: 3706-3714.
18. Guerin B, Dumulon-Perreault V, Tremblay M-C, Ait-Mohand S, Fournier P, et al. (2010) [Lys(DOTA)4]BVD15, a novel and potent neuropeptide Y analog designed for Y1 receptor-targeted breast tumor imaging. Bioorg Med Chem Lett 20: 950-953.
19. Keller M, Pop N, Hutzler C, Beck-Sickinger AG, Bernhardt G, et al. (2008) Guanidine-Acylguanidine Bioisosteric Approach in the Design of Radioligands: Synthesis of a Tritium-Labeled NG-Propionylargininamide ([3H]-UR-MK114) as a Highly Potent and Selective Neuropeptide Y Y1 Receptor Antagonist. J Med Chem 51: 8168-8172.
20. Rudolf K, Eberlein W, Engel W, Wieland HA, Willim KD, et al. (1994) The first highly potent and selective non-peptide neuropeptide Y Y1 receptor antagonist: BIBP3226. Eur J Pharmacol 271: R11-13.
21. Doods H, Gaida W, Wieland HA, Dollinger H, Schnorrenberg G, et al. (1999) BIIE0246: A selective and high affinity neuropeptide Y Y2 receptor antagonist. Eur J Pharmacol 384: R3-R5.
22. Criscione L, Rigollier P, Batzl-Hartmann C, Rueger H, Stricker-Krongrad A, et al. (1998) Food intake in free-feeding and energy-deprived lean rats is mediated by the neuropeptide Y5 receptor. J Clin Invest 102: 2136-2145.
23. Schneider E, Mayer M, Ziemek R, Li L, Hutzler C, et al. (2006) A simple and powerful flow cytometric method for the simultaneous determination of multiple parameters at G protein-coupled receptor subtypes. Chembiochem 7: 1400-1409.
24. Horwitz KB, McGuire WL, (1978) Estrogen control of progesterone receptor in human breast cancer. Correlation with nuclear processing of estrogen receptor. J Biol Chem 253: 2223-2228.
25. Bernhardt G, Reile H, Birnbock H, Spruss T, Schönenberger H, (1992) Standardized kinetic microassay to quantify differential chemosensitivity on the basis of proliferative activity. J Cancer Res Clin Oncol 118: 35-43.
26. Bradford MM, (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254.
27. Schneider E, Keller M, Brennauer A, Hoefelschweiger BK, Gross D, et al. (2007) Synthesis and characterization of the first fluorescent nonpeptide NPY Y1 receptor antagonist. Chembiochem 8: 1981-1988.
28. Müller M, Knieps S, Gessele K, Dove S, Bernhardt G, et al. (1997) Synthesis and neuropeptide Y Y1 receptor antagonistic activity of N,N-disubstituted omega-guanidino- and omega-aminoalkanoic acid amides. Arch Pharm (Weinheim) 330: 333-342.
29. Grynkiewicz G, Poenie M, Tsien RY, (1985) A new generation of Ca2+ indicators with greatly improved fluorescence properties. J Biol Chem 260: 3440-3450.
30. Bernhardt G, Spruss T, Rustler M, (1992) Comparison of MCF-7 and ZR-75-1 cell lines as models for studying hormone-dependent human breast cancer in nude mice. Contrib Oncol Basel, Karger 42: 128-130.
31. Aiglstorfer I, Hendrich I, Moser C, Bernhardt G, Dove S, et al. (2000) Structure-activity relationships of neuropeptide Y Y1 receptor antagonists related to BIBP 3226. Bioorg Med Chem Lett 10: 1597-1600.
32. Moser C, Bernhardt G, Michel J, Schwarz H, Buschauer A, (2000) Cloning and functional expression of the hNPY Y5 receptor in human endometrial cancer (HEC-1B) cells. Can J Physiol Pharmacol 78: 134-142.
33. Ziemek R, Brennauer A, Schneider E, Cabrele C, Beck-Sickinger AG, et al. (2006) Fluorescence- and luminescence-based methods for the determination of affinity and activity of neuropeptide Y2 receptor ligands. Eur J Pharmacol 551: 10-18.
34. Schobert R, Bernhardt G, Biersack B, Bollwein S, Fallahi M, et al. (2007) Steroid conjugates of dichloro(6-aminomethylnicotinate)platinum(II): effects on DNA, sex hormone binding globulin, the estrogen receptor, and various breast cancer cell lines. ChemMedChem 2: 333-342.
35. Bindal RD, Carlson KE, Katzenellenbogen BS, Katzenellenbogen JA, (1988) Lipophilic impurities, not phenolsulfonphthalein, account for the estrogenic activity in commercial preparations of phenol red. J Steroid Biochem 31: 287-293.
36. Stauffer SR, Coletta CJ, Tedesco R, Nishiguchi G, Carlson K, et al. (2000) Pyrazole ligands: structure-affinity/activity relationships and estrogen receptor-alpha-selective agonists. J Med Chem 43: 4934-4947.
37. Magni P, Motta M, (2001) Expression of neuropeptide Y receptors in human prostate cancer cells. Ann Oncol 12 (Suppl 2): S27-29.
38. Körner M, Waser B, Reubi JC, (2008) High expression of neuropeptide Y1 receptors in ewing sarcoma tumors. Clin Cancer Res 14: 5043-5049.
39. Körner M, Reubi JC, (2008) Neuropeptide Y receptors in primary human brain tumors: overexpression in high-grade tumors. J Neuropathol Exp Neurol 67: 741-749.
40. Harvey JM, Clark GM, Osborne CK, Allred DC, (1999) Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17: 1474-1481.
41. Entzeroth M, Braunger H, Eberlein W, Engel W, Rudolf K, et al. (1995) Labeling of neuropeptide Y receptors in SK-N-MC cells using the novel, nonpeptide Y1 receptor-selective antagonist [3H]BIBP3226. Eur J Pharmacol 278: 239-242.
42. Robertson JF, (2001) ICI 182,780 (Fulvestrant)-the first oestrogen receptor down-regulator-current clinical data. British Journal of Cancer 85 (Suppl 2): 11-14.
43. Wijayaratne AL, McDonnell DP, (2001) The human estrogen receptor-α is a ubiquitinated protein whose stability is affected differentially by agonists, antagonists, and selective estrogen receptor modulators. J Biol Chem 276: 35684-35692.
44. Driggers PH, Segars JH, (2002) Estrogen action and cytoplasmic signaling pathways. Part II: the role of growth factors and phosphorylation in estrogen signaling. Trends Endocrinol Metab 13: 422-427.
45. Kitlinska J, Abe K, Kuo L, Pons J, Yu M, et al. (2005) Differential effects of neuropeptide Y on the growth and vascularization of neural crest-derived tumors. Cancer Res 65: 1719-1728.
46. Kempna P, Korner M, Waser B, Hofer G, Nuoffer JM, et al. (2010) Neuropeptide Y modulates steroid production of human adrenal H295R cells through Y1 receptors. Mol Cell Endocrinol 314: 101-109.
47. Allan GF, Hutchins A, Liu X, Clancy J, (2001) Induction of the progesterone receptor gene in estrogen target cells monitored by branched DNA signal amplification. Steroids 66: 663-671.
48. Barkhem T, Carlsson B, Nilsson Y, Enmark E, Gustafsson J, et al. (1998) Differential response of estrogen receptor alpha and estrogen receptor beta to partial estrogen agonists/antagonists. Mol Pharmacol 54: 105-112.
49. Zimmermann J, Liebl R, von Angerer E, (2005) 2,5-Diphenylfuran-based pure antiestrogens with selectivity for the estrogen receptor alpha. J Steroid Biochem Mol Biol 94: 57-66.
50. Fowler AM, Chan SR, Sharp TL, Fettig NM, Zhou D, et al. (2012) Small-animal PET of steroid hormone receptors predicts tumor response to endocrine therapy using a preclinical model of breast cancer. J Nucl Med 53: 1119-1126.